Kidney Week 2024
Summaries from Kidney Week 2024, held from October 23 – 27, 2024.
A second course of budesonide had additional positive effects on proteinuria and kidney function in previously treated patients with immunoglobulin A nephropathy
Presenter: Richard A. Lafayette, MD, Stanford University, Stanford, CA
In patient with immunoglobulin A nephropathy previously treated with budesonide, a second 9-month treatment course had an additional positive effect on proteinuria and kidney function, according to this open-label extension study.
Long-term empagliflozin therapy reduces cardiorenal disease progression in patients with chronic kidney disease
Presenter: William G. Herrington, MD, University of Oxford, Oxford, Oxfordshire, United Kingdom
A 2-year follow-up study showed that empagliflozin continues to improve cardiorenal outcomes in patients with chronic kidney disease, even if it is discontinued.
Semaglutide reduced the risk of major kidney outcomes in patients with type 2 diabetes and chronic kidney disease regardless its severity: FLOW trial
Presenter: Katherine R. Tuttle, MD, Executive Director for Research, Providence Inland Northwest Health, Spokane, WA.
Semaglutide safely and effectively reduces the risks of major kidney outcomes regardless of chronic kidney disease (CKD) severity in patients with diabetes and CKD.
Pain coping skills can reduce pain in patients receiving hemodialysis: HOPE Consortium Randomized Trial
Presenter: Laura M. Dember, MD, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
Among patients undergoing maintenance hemodialysis, pain coping skills training can improve pain-associated outcomes at 12 weeks, according to the HOPE Consortium Randomized Trial.
Iptacopan both safe and effective for decreasing proteinuria in patients with immunoglobulin A nephropathy: APPLAUSE-IgAN trial
Presenter: Dana V. Risk, MD, University of Alabama at Birmingham, Birmingham, AL
Iptacopan decreased proteinuria by 35% in patients with immunoglobulin A nephropathy and low estimated glomerular filtration rates, making it a potential treatment option for these patients.
SLGT-2 inhibitors reduce mortality in patients with advanced chronic kidney disease
Presenter: Rochell Issa, MD, Cleveland Clinic, Cleveland, OH
Use of sodium-glucose cotransporter 2 inhibitors was associated with significantly reduced all-cause mortality in patients with advanced chronic kidney disease in this study.
Budesonide offers a safe and effective alternative to prednisone for treating immunoglobulin A nephropathy
Presenter: Abhi Lohana, MD, Camden Clark Medical Center, Parkersburg, West VA
In this study, budesonide was as effective as prednisone for treating patients with immunoglobulin A nephropathy and offers a more favorable safety profile.
In patients with chronic kidney disease, spironolactone reduces major cardiovascular events but increases all-cause mortality and severe hyperkalemia
Presenter: Tz-Heng Chen, MD, Taipei Veterans General Hospital, Taipei, Taiwan
Using spironolactone to treat patients with chronic kidney disease increased their risks of all-cause mortality and severe hyperkalemia but decreased the risk major adverse cardiovascular events, driven by lower stroke risk, in this retrospective study.
Sparsentan-treated patients with immunoglobulin A nephropathy had more clinically meaningful proteinuria improvements than those treated with irbesartan: PROTECT subgroup analysis
Presenter: Laura Kooienga, MD, Colorado Kidney Care, Denver, CO.
Regardless of the baseline proteinuria level in patients with immunoglobulin A nephropathy, sparsentan provided greater clinically meaningful benefits than irbesartan, according to a subgroup analysis of PROTECT study results.
Neurologists are using recently approved drugs to treat patients with immunoglobulin A neuropathy but see an unmet need for more innovation: Survey
Presenter: Justin Snyder, MD, Spherix Global Insights, Exton, PA.
Nephrologists continue to see an unmet need for new drugs that effectively treat the root cause of immunoglobulin A neuropathy and that further enable practitioners to individualize treatments.
Iptacopan shows favorable efficacy and safety results in patients with C3 glomerulopathy: 12-month data from the phase 3 APPEAR-C3G study
Presenter: Carla M. Nester, MD, University of Iowa Stead Family Children's Hospital, Iowa City, Iowa.
Iptacopan-treated patients had significant and clinically meaningful proteinuria reduction at 6 months that was sustained for 12 months.
Effect of iptacopan on proteinuria and complement biomarkers in IgAN: Interim analysis of the phase 3 APPLAUSE-IgAN study
Presenter: Dana V. Rizk, MD, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Iptacopan inhibits systemic and intrarenal activation of the alternative complement pathway in patients with immunoglobulin A nephropathy.
Finerenone reduces the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes and chronic kidney disease
Presenter: Ajay K. Singh, MD, Harvard Medical School, Boston, Massachusetts.
Concomitant use of finerenone with an SGLT-2 inhibitor plus GLP-1RA may provide additional kidney benefits in patients with diabetes and chronic kidney disease.